WHWK — Whitehawk Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $67.84m
- $20.60m
- $25.98m
- 32
- 32
- 14
- 15
Annual income statement for Whitehawk Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15 | 1.12 | 15.2 | 24.4 | 26 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 13.9 | 21.5 | 23 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 21.4 | 112 | 77.9 | 96.3 | 93.4 |
| Operating Profit | -6.36 | -111 | -62.7 | -71.9 | -67.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.32 | -110 | -60.5 | -65.8 | -63.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.32 | -110 | -60.5 | -65.8 | -63.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.32 | -110 | -60.5 | -65.8 | -63.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.32 | -110 | -60.5 | -65.8 | -63.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.52 | -6.95 | -2.52 | -2.44 | -2.26 |